Susen A. Becker

Leipzig, SN, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications

Preliminary pharmacokinetic investigations of hydroxylated metabolites after controlled inhalative and oral consumption of hexahydrocannabinol (HHC).

Preliminary pharmacokinetic investigations of hydroxylated metabolites after controlled inhalative and oral consumption of hexahydrocannabinol (HHC).

Journal: Scientific reports
Published: April 30, 2026

Optogenetic Inhibition of Striatal Parvalbuminergic Interneurons Unmasks Impaired GABA and Adenosine Signaling in DYT1 Knock-In Mice.

Optogenetic Inhibition of Striatal Parvalbuminergic Interneurons Unmasks Impaired GABA and Adenosine Signaling in DYT1 Knock-In Mice.

Journal: International journal of molecular sciences
Published: April 11, 2026

Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC

Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC

Journal: Laryngo- rhino- otologie
Published: April 02, 2026

Driving under the influence of alcohol and drugs on e-scooters: a toxicological perspective of public health and road safety in Leipzig, Germany.

Driving under the influence of alcohol and drugs on e-scooters: a toxicological perspective of public health and road safety in Leipzig, Germany.

Journal: International journal of legal medicine
Published: March 30, 2026

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Journal: Allergy
Published: January 21, 2026

Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 3: Hypersensitivity reactions of type VI

Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 3: Hypersensitivity reactions of type VI

Journal: HNO
Published: July 29, 2025

Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 2: Hypersensitivity reactions of type V (epithelial barrier defects)

Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 2: Hypersensitivity reactions of type V (epithelial barrier defects)

Journal: HNO
Published: July 29, 2025

Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany.

Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany.

Journal: Rhinology
Published: July 07, 2025

The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways-An EAACI Position Paper.

The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways-An EAACI Position Paper.

Journal: Allergy
Published: May 02, 2025

Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 1: Hypersensitivity reactions of type IVa-c as a correlate to T1, T2, and T3 endotypes

Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 1: Hypersensitivity reactions of type IVa-c as a correlate to T1, T2, and T3 endotypes

Journal: HNO
Published: February 18, 2025

Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity-An EAACI Position Paper.

Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity-An EAACI Position Paper.

Journal: Allergy
Published: December 12, 2024

Preliminary pharmacokinetic and psychophysical investigations after controlled oral and inhalative consumption of hexahydrocannabinol (HHC).

Preliminary pharmacokinetic and psychophysical investigations after controlled oral and inhalative consumption of hexahydrocannabinol (HHC).

Journal: Scientific reports
Published: December 09, 2024
Showing 1-12 of 81

Last Updated: 09/26/2026